Wang Yanning, Gong Xiaoling, Hu Yuxuan, Yi Qing, Zhang Qianning, Miao Liyun, Zhou Yujie
Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Front Oncol. 2022 Jun 20;12:873709. doi: 10.3389/fonc.2022.873709. eCollection 2022.
Interstitial lung disease (ILD) is the most serious complication of chemotherapy in lung cancer patients with pre-existing ILD. The effect of anti-angiogenic drugs in lung cancer patients with ILD remains unclear. We examined the effect of anti-angiogenic drugs on reducing the risk of ILD progression in non-small cell lung cancer (NSCLC) patients receiving chemotherapy.
We analyzed the risk of ILD progression in 52 patients with advanced NSCLC with ILD who received first-line chemotherapy with (anti-angiogenic group, n = 22) and without (non-anti-angiogenic group, n = 30) anti-angiogenic drugs between August 2014 and January 2021.
The incidences of chemotherapy-related ILD progression were significantly lower in the anti-angiogenic than in the non-anti-angiogenic groups (0% vs. 20.0%, p = 0.033). However, there were no differences in other events as the competing risk factors of ILD progression between the two groups. The overall-cumulative incidence of ILD progression during the first-line and subsequent chemotherapy was 30.8% (16 of the 52). The median progression-free survival had no significant difference between the anti-angiogenic and the non-anti-angiogenic groups (10.3 vs. 8.1 months, p = 0.386).
The addition of anti-angiogenic drugs to chemotherapy regimens may reduce the risk of chemotherapy-related ILD progression in patients with NSCLC-ILD.
间质性肺疾病（ILD）是已有ILD的肺癌患者化疗最严重的并发症。抗血管生成药物对患有ILD的肺癌患者的影响尚不清楚。我们研究了抗血管生成药物对降低接受化疗的非小细胞肺癌（NSCLC）患者ILD进展风险的作用。
我们分析了2014年8月至2021年1月期间52例患有ILD的晚期NSCLC患者一线化疗时使用（抗血管生成组，n = 22）和未使用（非抗血管生成组，n = 30）抗血管生成药物的ILD进展风险。
抗血管生成组化疗相关ILD进展的发生率显著低于非抗血管生成组（0%对20.0%，p = 0.033）。然而，两组之间作为ILD进展竞争风险因素的其他事件没有差异。一线及后续化疗期间ILD进展的总体累积发生率为30.8%（52例中的16例）。抗血管生成组和非抗血管生成组的无进展生存期无显著差异（10.3对8.1个月，p = 0.386）。
化疗方案中添加抗血管生成药物可能会降低NSCLC-ILD患者化疗相关ILD进展的风险。
